CTOs on the Move

Attralus

www.attralus.com

 
Amyloid diseases are a diverse group of disorders, characterized by the deposition of amyloid protein fibrils in vital organs and tissues. There are approximately 30 different types of amyloidosis, each resulting from the misfolding and aggregation of a specific protein, and they are all severely debilitating, progressive, and often fatal.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.attralus.com
  • ‍329 Oyster Point Blvd Third Floor
    South San Francisco, BC USA 94080
  • Phone: N/A

Executives

Name Title Contact Details

Funding

Attralus raised $25M on 09/14/2020

Similar Companies

Biocompare

Biocompare is a South San Francisco, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Apeel Sciences

We use our natural plant-based technologies to protect crops and harvested produce, helping to eliminate food spoilage and reduce reliance on chemicals. Accomplishing our mission means we will waste less food, water and energy, helping to preserve our natural ecosystems while creating economic opportunities for the 500 million small family farms worldwide. In the future, less food will be wasted, we will use smarter, more natural methods for growing and protecting crops, and there will be an abundance of fresh food for everyone.

Transave

Transave is a Monmouth Junction, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Celularity

Celularity, headquartered in Florham Park, N.J., is a clinical stage biotechnology company leading the next evolution in cellular medicine by delivering off-the-shelf allogeneic placenta-derived cellular therapies at unparalleled scale, quality and economics. Celularity`s innovative approach to cell therapy harnesses the unique therapeutic potential locked within the postpartum placenta. Through nature`s immunotherapy engine – the placenta – Celularity is leading the next evolution of cellular medicine with placenta-derived T cells, NK cells, and pluripotent stem cells to target unmet and underserved clinical needs in cancer, infectious and degenerative diseases.

Cullinan Oncology

Cullinan Oncology is focused on investing in and developing a highly diversified portfolio of oncology therapeutics with a unique, cost-efficient business model. Sourced from the Cullinan dry lab as well as external collaborators, Cullinan`s assets are managed by a single, highly experienced team of oncology professionals and drug developers across a lean, capital efficient operating model.